​Effective January 1, 2027, AmeriHealth HMO, Inc. and AmeriHealth Insurance Company of New Jersey (collectively, AmeriHealth) and AmeriHealth Administrators will update the Select Drug Program® Formulary and Value Formulary. The changes include updates to the formulary status of several brand-name medica​tions where generic alternatives will be available.

Januvia® and Janumet® [XR]

Effective January 1, 2027, Januvia® and Janumet® [XR] will become non-preferred on the Select Drug Program Formulary and require prior authorization and will become non-formulary on the Value Formulary. Formulary update letters are being sent to impacted members and their providers.

• Generic alternatives available:

• Januvia: Sitagliptin

• Janumet: Sitagliptin and metformin
  

Januvia and Janumet [XR] are indicated for the treatment of type 2 diabetes mellitus.

Farxiga® and Xigduo® XR

Effective January 1, 2027, Farxiga® and Xigduo® XR will become non-preferred on the Select Drug Program Formulary and require prior authorization and will become non-formulary on the Value Formulary.

• Generic alternatives available:

• Farxiga: Dapagliflozin

• Xigduo XR: Dapagliflozin and metformin

Farxiga and Xigduo XR have indications related to type 2 diabetes mellitus, cardiovascular risk, heart failure, and chronic kidney disease.

Learn more

Providers can review the full formularies on the AmeriHealth website, where formularies are available to download as PDFs or search by drug name.

For patients with an AmeriHealth Administrators ID card, visit the AmeriHealth Administrators prescription drug information website to review formulary information.

Visit AmeriHealth to learn more about our pharmacy policies and programs.

26-0200

​